Study: Levofloxacin induced least toxicity, apoptosis

Article

In a study performed to evaluate and compare preserved versus unpreserved fluoroquinolone antibiotics, cell culture assays demonstrated some degree of toxicity and elevated induction of apoptosis in each of three commercially available topical ocular fluoroquinolone antibiotics, according to one expert.

Fort Lauderdale, FL-In a study performed to evaluate and compare preserved versus unpreserved fluoroquinolone antibiotics, cell culture assays demonstrated some degree of toxicity and elevated induction of apoptosis in each of three commercially available topical ocular fluoroquinolone antibiotics, according to Seth P. Epstein, MD, who presented a poster on his work with colleagues at the annual meeting of the Association for Research in Vision and Ophthalmology.

Of the three, nonpreserved levofloxacin ophthalmic solution 1.5% (Iquix, Santen/Vistakon Pharmaceuticals) induced the least toxicity and apoptosis, followed closely by nonpreserved moxifloxacin ophthalmic solution 0.5% (Vigamox, Alcon Laboratories), while gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan), which is preserved with 0.005% benzalkonium chloride (BAK), had the greatest levels of both toxicity and apoptosis, said Dr. Epstein, assistant professor of ophthalmology, Mount Sinai School of Medicine, New York, NY.

"There's been a great deal in the literature about the toxicity of BAK," Dr. Epstein said. "Previous work in our lab has determined that of the five classes of preservatives that are in use, BAK is one of the most toxic. It also is one of the most commonly used.

In this study, the investigators evaluated the toxicity and apoptosis induced by the antibiotics using a cell culture model consisting of an MTT (method of transcriptional and translational) cytotoxicity assay and a TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) apoptosis assay. Preconfluent immortalized conjunctival and human corneal epithelial cells were each incubated with the three commercial antibiotic preparations.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.